The company said it will use the funds to expand its menu of STI tests and launch its io rapid diagnostic platform into UK sexual health clinics.
The firm recently won an NIH grant to develop its instrument-free gonorrhea test, and is also developing a chlamydia assay with the long-term goal of making a combined CT/NG test.
The funding comes from a syndicate which includes all Series C investors and one new investor, Chinese assay developer Wondfo Biotech.
The test runs on the firm's high throughput platforms and has claims for extragenital samples in addition to traditional samples.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
Diagnostic systems strength was driven by strong growth in molecular and installations in Western Europe .
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
Genome sequences from Neisseria gonorrhoeae isolates from the UK provided insights into transmission and resistance patterns.
Under the agreement, Goffin will distribute SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR product lines in Benelux.
Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.
Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.
In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.
Iceland has nearly eliminated Down syndrome from its population, CBS News reports.
